Opioid-induced respiratory depression increases hospital costs and length of stay in patients recovering on the general care floor.
Costs
Detection
Healthcare utilization
Monitoring
Opioids
Patient safety
Post-operative
Respiratory depression
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
20 03 2021
20 03 2021
Historique:
received:
17
12
2020
accepted:
12
03
2021
entrez:
21
3
2021
pubmed:
22
3
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Opioid-induced respiratory depression is common on the general care floor. However, the clinical and economic burden of respiratory depression is not well-described. The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial created a prediction tool to identify patients at risk of respiratory depression. The purpose of this retrospective sub-analysis was to examine healthcare utilization and hospital cost associated with respiratory depression. One thousand three hundred thirty-five patients (N = 769 United States patients) enrolled in the PRODIGY trial received parenteral opioids and underwent continuous capnography and pulse oximetry monitoring. Cost data was retrospectively collected for 420 United States patients. Differences in healthcare utilization and costs between patients with and without ≥1 respiratory depression episode were determined. The impact of respiratory depression on hospital cost per patient was evaluated using a propensity weighted generalized linear model. Patients with ≥1 respiratory depression episode had a longer length of stay (6.4 ± 7.8 days vs 5.0 ± 4.3 days, p = 0.009) and higher hospital cost ($21,892 ± $11,540 vs $18,206 ± $10,864, p = 0.002) compared to patients without respiratory depression. Patients at high risk for respiratory depression, determined using the PRODIGY risk prediction tool, who had ≥1 respiratory depression episode had higher hospital costs compared to high risk patients without respiratory depression ($21,948 ± $9128 vs $18,474 ± $9767, p = 0.0495). Propensity weighted analysis identified 17% higher costs for patients with ≥1 respiratory depression episode (p = 0.007). Length of stay significantly increased total cost, with cost increasing exponentially for patients with ≥1 respiratory depression episode as length of stay increased. Respiratory depression on the general care floor is associated with a significantly longer length of stay and increased hospital costs. Early identification of patients at risk for respiratory depression, along with early proactive intervention, may reduce the incidence of respiratory depression and its associated clinical and economic burden. ClinicalTrials.gov , NCT02811302 .
Sections du résumé
BACKGROUND
Opioid-induced respiratory depression is common on the general care floor. However, the clinical and economic burden of respiratory depression is not well-described. The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial created a prediction tool to identify patients at risk of respiratory depression. The purpose of this retrospective sub-analysis was to examine healthcare utilization and hospital cost associated with respiratory depression.
METHODS
One thousand three hundred thirty-five patients (N = 769 United States patients) enrolled in the PRODIGY trial received parenteral opioids and underwent continuous capnography and pulse oximetry monitoring. Cost data was retrospectively collected for 420 United States patients. Differences in healthcare utilization and costs between patients with and without ≥1 respiratory depression episode were determined. The impact of respiratory depression on hospital cost per patient was evaluated using a propensity weighted generalized linear model.
RESULTS
Patients with ≥1 respiratory depression episode had a longer length of stay (6.4 ± 7.8 days vs 5.0 ± 4.3 days, p = 0.009) and higher hospital cost ($21,892 ± $11,540 vs $18,206 ± $10,864, p = 0.002) compared to patients without respiratory depression. Patients at high risk for respiratory depression, determined using the PRODIGY risk prediction tool, who had ≥1 respiratory depression episode had higher hospital costs compared to high risk patients without respiratory depression ($21,948 ± $9128 vs $18,474 ± $9767, p = 0.0495). Propensity weighted analysis identified 17% higher costs for patients with ≥1 respiratory depression episode (p = 0.007). Length of stay significantly increased total cost, with cost increasing exponentially for patients with ≥1 respiratory depression episode as length of stay increased.
CONCLUSIONS
Respiratory depression on the general care floor is associated with a significantly longer length of stay and increased hospital costs. Early identification of patients at risk for respiratory depression, along with early proactive intervention, may reduce the incidence of respiratory depression and its associated clinical and economic burden.
TRIAL REGISTRATION
ClinicalTrials.gov , NCT02811302 .
Identifiants
pubmed: 33743588
doi: 10.1186/s12871-021-01307-8
pii: 10.1186/s12871-021-01307-8
pmc: PMC7980593
doi:
Substances chimiques
Analgesics, Opioid
0
Banques de données
ClinicalTrials.gov
['NCT02811302']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Références
Anesth Analg. 2017 Dec;125(6):2019-2029
pubmed: 29064874
Pharmacotherapy. 2012 Sep;32(9 Suppl):12S-8S
pubmed: 22956490
J Crit Care. 2018 Oct;47:80-87
pubmed: 29936327
Anesthesiology. 2009 Apr;110(4):759-65
pubmed: 19322941
Anesth Analg. 2015 Sep;121(3):709-15
pubmed: 26287299
Anesthesiology. 2015 Mar;122(3):659-65
pubmed: 25536092
J Pain Symptom Manage. 2003 Mar;25(3):276-83
pubmed: 12614962
J Pain Palliat Care Pharmacother. 2013 Mar;27(1):62-70
pubmed: 23302094
Eur J Anaesthesiol. 2015 Jul;32(7):458-70
pubmed: 26020123
Resuscitation. 2016 Aug;105:123-9
pubmed: 27255952
J Clin Anesth. 2011 May;23(3):207-13
pubmed: 21570616
J Manag Care Spec Pharm. 2014 Sep;20(9):948-58
pubmed: 25166294
J Anesth. 2016 Feb;30(1):116-22
pubmed: 26449674
Ann Pharmacother. 2007 Mar;41(3):400-6
pubmed: 17341537
Med Care Res Rev. 2011 Aug;68(4):490-503
pubmed: 21536599
Crit Care. 2019 May 30;23(1):194
pubmed: 31146792
JAMA. 2019 Mar 26;321(12):1200-1210
pubmed: 30912843
Pharmacotherapy. 2013 Apr;33(4):383-91
pubmed: 23553809
PLoS One. 2017 May 17;12(5):e0175408
pubmed: 28520718
J Pain Palliat Care Pharmacother. 2014 Sep;28(3):282-93
pubmed: 25102043
Anesthesiology. 2010 Feb;112(2):282-7
pubmed: 20098128
Anesth Analg. 2016 Dec;123(6):1471-1479
pubmed: 27607476
Lancet. 2012 Sep 22;380(9847):1059-65
pubmed: 22998715
BMJ Open. 2018 Dec 14;8(12):e024086
pubmed: 30552274
Anesth Analg. 2015 Aug;121(2):422-9
pubmed: 25993390
Resuscitation. 2016 Jan;98:112-7
pubmed: 26362486
Health Aff (Millwood). 2015 Jun;34(6):922-8
pubmed: 26056196
Perioper Med (Lond). 2016 Aug 02;5:19
pubmed: 27486512
J Patient Saf. 2021 Mar 1;17(2):e76-e83
pubmed: 30672762
Anesth Analg. 2020 Oct;131(4):1012-1024
pubmed: 32925318
Br J Anaesth. 2004 Aug;93(2):212-23
pubmed: 15169738
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Anesth Analg. 2016 Jan;122(1):145-51
pubmed: 26111263
J Patient Saf. 2017 Jul 20;:
pubmed: 28731933
Am J Emerg Med. 2009 Sep;27(7):843-6
pubmed: 19683114
JAMA Surg. 2018 Aug 1;153(8):757-763
pubmed: 29799927